US 12,066,442 · Application 17/393,335 · Granted Aug 20, 2024
US 12,066,442
Method of assessing risk of pml
Estimated expiration
May 31, 2032
5y 245d remaining
Earliest effective filing
May 31, 2012
+ 20 years
May 31, 2032
PTA +0d
May 31, 2032
TD applied
May 31, 2032
Final
May 31, 2032
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- August 3, 2021
- Earliest effective filing
- May 31, 2012
- Issue date
- August 20, 2024
- PTA
- 0 days
- Base expiry (before PTA)
- May 31, 2032
May 31, 2012 + 20 years = May 31, 2032
- Divisional of application 16/211,154, filed Dec 5, 2018, issued as US 12,105,090
- Continuation of application 14/122,754, filed Jun 23, 2014
- National stage entry of application PCTUS2012040283, filed May 31, 2012
- National stage entry of application PCTUS2012040283, filed May 31, 2012
- Continuation of application 14/122,754, filed Jun 23, 2014
- National stage entry of application PCTUS2012040283, filed May 31, 2012
- PRO61/550,257 — Provisional — not used for base term
- PRO61/491,810 — Provisional — not used for base term
- PRO61/508,584 — Provisional — not used for base term
- PRO61/636,588 — Provisional — not used for base term
- PRO61/491,810 — Provisional — not used for base term
- PRO61/508,584 — Provisional — not used for base term
- PRO61/550,257 — Provisional — not used for base term
- PRO61/636,588 — Provisional — not used for base term
- PRO61/491,810 — Provisional — not used for base term
- PRO61/508,584 — Provisional — not used for base term
- PRO61/550,257 — Provisional — not used for base term
- PRO61/636,588 — Provisional — not used for base term
- PRO61/636,588 — Provisional — not used for base term
- PRO61/550,257 — Provisional — not used for base term
- PRO61/508,584 — Provisional — not used for base term
- PRO61/491,810 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to May 31, 2032
US 12,066,442· Application 17/393,335(from application 17/393,335)Capping patent
Method of assessing risk of pml
- Filing date
- Aug 3, 2021
- Earliest effective filing
- May 31, 2012
- Issue date
- Aug 20, 2024
- PTA
- 0 days
- Calculated expiration
- May 31, 2032
Divisional of 16/211,154, filed Dec 5, 2018, issued as US 12,105,090
Continuation of 14/122,754, filed Jun 23, 2014
National stage entry of PCTUS2012040283, filed May 31, 2012
National stage entry of PCTUS2012040283, filed May 31, 2012
Continuation of 14/122,754, filed Jun 23, 2014
National stage entry of PCTUS2012040283, filed May 31, 2012
May 31, 2012 + 20y = May 31, 2032
US 12,105,090· Application 16/211,154(from application 16/211,154)
Methods of treating a multiple sclerosis patient with anti-vla-4 therapy
- Filing date
- Dec 5, 2018
- Earliest effective filing
- May 31, 2012
- Issue date
- Oct 1, 2024
- PTA
- +751 days
- Calculated expiration
- Jun 21, 2034
Continuation of 14/122,754, filed Jun 23, 2014
National stage entry of PCTUS2012040283, filed May 31, 2012
National stage entry of PCTUS2012040283, filed May 31, 2012
May 31, 2012 + 20y + 751d PTA = Jun 21, 2034
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/393,335 · US 12,066,442
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,066,442: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12066442Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.